<DOC>
	<DOCNO>NCT00003868</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Donor stem cell transplantation may able replace immune cell destroy radiolabeled monoclonal antibody therapy , chemotherapy radiation therapy . PURPOSE : Phase II trial study effectiveness combine radiolabeled monoclonal antibody cyclophosphamide total-body irradiation follow donor stem cell transplantation treat patient advance acute myeloid leukemia .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody , Cyclophosphamide , Total Body Irradiation Followed By Donor Stem Cell Transplantation Treating Patients With Advanced Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy , term overall survival disease-free survival , toxicity cyclophosphamide total body irradiation patient acute myeloid leukemia beyond first remission receive HLA-matched related unrelated hematopoietic stem cell transplantation . - Determine maximum tolerate dose ( MTD ) iodine I 131 monoclonal antibody BC8 ( I131 MOAB BC8 ) patient . - Estimate MTD radiation deliver I 131 MOAB BC8 marrow patient assess effect growth marrow stroma vitro . OUTLINE : This radiation dose-escalation study . Patients stratify accord available donor ( related v unrelated ) . Patients receive biodistribution dose iodine I 131 monoclonal antibody BC8 ( I131 MOAB BC8 ) IV , therapeutic dose I131 MOAB BC8 IV 6-14 day later ( day -12 ) . Patients undergo total body irradiation twice daily day -6 -4 . Patients receive cyclophosphamide IV day -3 -2 . Bone marrow cell ( peripheral blood stem cell ) infuse day 0 . Patients CNS leukemic involvement receive intrathecal methotrexate twice transplantation every week 8 week begin day 32 . These patient also receive cranial irradiation begin day 32 . Cohorts 4 patient receive escalate dos iodine I 131 attached standard dose monoclonal antibody BC8 maximum tolerate dose ( MTD ) determine . The MTD define radiation dose precede 2 6 patient experience graft failure . Patients follow 6 , 9 , 12 month , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient ( 20 per stratum ) accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia ( AML ) beyond first remission OR primary refractory disease AML transform myelodysplastic syndrome , induction chemotherapy recommend Documented CD45 expression patient relapse disease Not need patient remission Circulating blast count le 10,000/mm^3 ( may control hydroxyurea similar agent ) PATIENT CHARACTERISTICS : Age 2 55 Performance status Not specify Life expectancy More 60 day Hematopoietic See Disease Characteristics Hepatic Bilirubin le 1.5 mg/dL ( unless bilirubin determine gastroenterology service predominantly unconjugated [ indirect ] result possible hemolysis ) AST le 1.5 time upper limit normal ( ULN ) Renal Creatinine le 2.0 mg/dL OR le 1.5 time ULN age Other Not pregnant nursing Fertile patient must use effective contraception No major infection No circulating antibody mouse immunoglobulin HIV negative Able tolerate diagnostic therapeutic procedure ( e.g. , radiation isolation ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy No radiotherapy maximum tolerated level normal organ Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>